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ABSTRACT 
Without any treatment, the prognosis of hepatitis B in liver
transplant recipients is very poor. So, antiviral prophylaxis is very
important in patients with hepatitis B who undergo liver trans-
plantation. Before liver transplantation, a suppression of viral
replication has to be achieved by nucleos(t)ide analogs. Drugs used
in the prophylaxis of post-transplant hepatitis B include im-
munoglobulin against HBV and nucleos(t)ide analogs. Prophylaxis
against graft infection must be based on the individual risk of re-
currence. When prophylactic measures have failed and graft infec-
tion has occurred, treatment of recurrent hepatitis B may be
based on the resistance profile of the virus and previous antiviral
exposure. Finally, lamivudine seems to be very effective in the
prevention of de novo hepatitis B in patients transplanted with a
graft from an anti-HBc positive donor.
Key words: Hepatitis B. Prophylaxis. Liver transplantation.
ABBREVIATIONS
HBV: hepatitis B virus
DNA: dexosiribonucleic acid
HDV: hepatitis D virus
Anti-HBs: antibodies against HBV surface antigen 
HBeAg: antibodies against HBV e antigen 
anti-HBc: antibodies against core antigen 
MELD: Model for End-stage Liver Disease
INTRODUCTION
Hepatitis B virus (HBV)-related liver cirrhosis accounts
for 5-10% of liver transplantations performed in Spain (1).
Until latest ’80s prognosis of transplant recipients for
HBV-related cirrhosis was very poor, and graft loss due to
recurrent HBV infection was the rule. In the last two
decades, the availability of hyperimmune immunoglobulin
and oral antiviral agents, have definitely changed the prog-
nosis of liver transplantation for HBV-related diseases.
Currently, 5-years survival rate is around 85%, compared
to 45% at 3 years before the immu noglobulin era (1,2).
Hepatitis B recurrence still plays an important role in
determining survival after liver transplantation, and
in some series it has been suggested that recurrent hepati-
tis B may have a role in promoting recurrence of liver
cancer (3) and lymphoproliferative disorders after trans-
plantation (4). Antiviral treatment, before and after liver
transplantation, markedly reduces the risk of hepatitis B
recurrence. High levels of HBV-DNA and presence of
HBV e antigen (HBeAg) at the time of liver transplanta-
tion, as well as HBV-related liver cirrhosis are the most
important predictors of hepatitis B recurrence (5,6). Con-
versely, acute liver failure and HBV-HDV coinfection
have been regarded as protective factors. 
In the early ’90, a multicenter European study showed
a 32% recurrence rate among HBV-hepatitis D virus
(HDV) coinfected patients compared to 53% in patients
with HBV infection alone (6). The protective role of
HDV infection has been shown only in liver cirrhosis, but
not in acute hepatitis B, and it is supposed to be related to
the inhibition of HBV replication (7). 
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In the setting of liver transplantation, three different
clinical situations have to be distinguished: a) treatment
of HBV infection during waiting list; b) prophylaxis of
hepatitis B recurrence after liver transplantation; and c)
treatment of recurrent hepatitis B when prophylactic
measures have failed. Moreover, de novo hepatitis B can
occur when liver from donors with antibodies against the
HBV core antigen (anti-HBc) are transplanted. This
donors account for 10-12% of the livers transplanted in
Spain (1).
TREATMENT OF HEPATITIS B PRIOR TO
LIVER TRANSPLANTATION
The availability of oral antiviral drugs, in the latest
decades, has definitely changed the management of HBV-
liver cirrhosis. Lamivudine, the first oral antiviral agent
against HBV, is safe and well tolerated even in patients
with decompensated liver cirrhosis (8). Patients with de-
compensated HBV-liver cirrhosis may benefit of lamivu-
dine treatment: their liver function may improve, compli-
cations of liver cirrhosis may resolve and, in some cases,
liver transplantation is not longer needed (9-11). Hyper-
immune immunoglobulin and nucleos(t)ide analogs, ad-
ministered after liver transplantation, dramatically reduce
the risk of hepatitis B recurrence; however, patients with a
high HBV-viral load at the time of liver transplantation
have a high risk of recurrent hepatitis, des pite prophylaxis
(6,12). 
For this reason, the main national and international hepa-
tology societies (Asociación Española para el Estudio del
Hígado, AEEH, American Association for the Study of Liv-
er Diseases, AASLD, and European Association for the
Study of the Liver, EASL) recommend the aggressive treat-
ment of HBV infection before liver transplantation (13-15).
The goal of antiviral therapy during waiting list is dou-
ble: first, to minimize viral replication prior to transplan-
tation (ideally achieving a total suppression of viral repli-
cation), and secondly, to improve liver function in order
to reduce mortality during waiting list (16). In the setting
of liver transplantation, as well as in other clinical situa-
tions, the choice of antiviral drugs depends on the severi-
ty of liver cirrhosis. Patients with chronic hepatitis or
compensated liver cirrhosis, that usually have hepatocel-
lular carcinoma, should be treated equally to patients not
listed for liver transplantation. Highly potent antiviral
agents (e.g. entecavir, tenofovir or telbivudine) are rec-
ommended as monotherapy or as combination therapy,
according to the presence of comorbidities and the resis-
tance profile of HBV. However, safety and efficacy data
of these new antiviral agents are not yet available. As a
consequence, lamivudine and adefovir are the only two
agents approved for the treatment of decompensated liver
cirrhosis and lamivudine is the most used. 
A major concern of long-term lamivudine therapy is
the high resistance rate that reaches 10-20% at 1 year and
is above 60% after 4 years of treatment. Although the
long-term resistance rate should not be an issue in a wait-
ing list setting, a 10% of lamivudine-resistance rate has
been reported among a series of wait-listed patients, be-
cause of the emergence of resistant strains after 1 year of
treatment (9,11,17). In addition, the duration of waiting
time is not predictable and the HBV reactivation in cir-
rhotics could result in high mortality and morbidity (18).
So, although it is approved for HBV decompensated liver
cirrhosis, lamivudine alone is not longer recommended in
this setting and its association with adefovir is strongly
suggested (14).
Adefovir is effective for lamivudine-resistant strains,
resulting in the suppression of viral replication. Adefovir
has been successfully used in patients with advanced cir-
rhosis and lamivudine-resistant hepatitis B, leading to an
improvement of liver function as shown by the reduction
of Child-Pugh score (19). The main concern about ade-
fovir treatment is the risk or kidney dysfunction. In addi-
tion, compared to other antiviral agents, the time to
achieve a complete viral suppression with adefovir could
be longer (20,21).
New oral antiviral agents seem a promising possibility
for the future in the treatment of wait-listed patients,
however they are not already approved for the use in de-
compensated liver cirrhosis. Among these, entecavir is
highly and rapidly effective, and it could be used when a
rapid viral suppression is required or in patients showing
neprotoxicity related to adefovir. It has been recently
showed highly effective on inhibiting viral replication
among cirrhotic patients. However its safety among pa-
tients with poor liver function remain uncertain, because
of some reports of lactic acidosis in severely decompen-
sated liver disease (MELD > 18) (22,23).
Compared to entecavir, tenofovir is more effective
among lamivudine-resistant strains, and it has a better
therapeutic index in patients with impaired renal func-
tion, compared to adefovir (24). 
Because of their efficacy and safety, entecavir and
tenofovir, used as monotherapy or in combination, are
considered as the first choice agents, in patients with
chronic hepatitis or compensated liver cirrhosis listed for
liver transplantation.
Finally, telbivudine has shown powerful antiviral ac-
tivity, with lower resistance rates compared to lamivu-
dine. One of the major advantages of telbivudine is its ac-
tivity against adefovir-resistant strains. It is approved for
use in compensated liver disease but, safety data in pa-
tients with decompensated liver disease are not available
to date (21). 
While treatment of chronic liver disease during wait-
ing list is universally accepted, there is not a general con-
sensus about treatment of patients with acute liver failure
who are listed for liver transplantation. As mentioned be-
fore, the risk of recurrent hepatitis B in patients trans-
planted for acute hepatitis B is lower than that observed
in patients transplanted for liver cirrhosis. However some
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recent reports suggest a possible role of antiviral agents
in improving the prognosis of acute liver failure and its
use in this setting is currently debated (6,25,26). 
Summarizing, in patients in waiting list for liver trans-
plantation, the choice of antiviral agent should take into
account the degree of liver dysfunction. For patients with
compensated liver disease (i.e., compensated liver cirrho-
sis or chronic hepatitis) a high potency antiviral agent,
such as entecavir, tenofovir and telbivudine, is strongly
recommended, according to comorbidities and the resis-
tance profile.
In patients with decompensated liver cirrhosis, the as-
sociation of lamivudine and adefovir is considered the
first line therapy, at least in naïve patients not requiring
an immediate viral suppression. Newer antiviral agents,
not already approved for decompensated liver cirrhosis,
are an attractive option for patients listed for liver trans-
plantation, especially when a rapid viral suppression is
needed, in presence of resistance to lamivudine or ade-
fovir or in patients with contraindications to these two
agents.
PROPHYLAXIS OF HEPATITIS B RECURRENCE
AFTER LIVER TRANSPLANTATION
Ideally, the treatment of patients on the waiting list
achieves a complete suppression of viral replication at
the time of liver transplantation. Pre-transplant treatment
reduces the recurrence rate in the graft (6,12). Neverthe-
less, to prevent hepatitis B recurrence, prophylactic mea-
sures have to be taken immediately after liver transplan-
tation.
Hyperimmune immunoglobulin against HBV has been
the first effective treatment in the prophylaxis of hepatitis
B recurrence after liver transplantation. Nowadays, im-
munoglobulin are the most used drug in this clinical set-
ting; however there is no a general agreement on dose,
administration route and treatment schedules that have to
be used (27,28). 
Unfortunately, the use of immunoglobulin alone, even
with long-term administration, results in 36 and 56% of
recurrence rate at 3 and 5-years after liver transplanta-
tion, at least among patients with high recurrence risk
(i.e. patients with positive HBV-DNA at the time of trans-
plantation, or in patients with HBeAg) (6).
The efficacy of lamivudine as monotherapy is similar
to that of immunoglobulin alone, leading to a 40-50% of
recurrence at 3-years after transplantation (29,30). The
combination of both has emerged as the most effective
prophylactic strategy in HBV transplant recipients, re-
sulting in a 3-years recurrence rate of 0-10% in the ma-
jority of published series (31-33).
The major concerns with the immunoglobulin therapy
are the high cost and the administration route (parenter-
al), especially when considering the need of long term
prophylaxis. Consequently, in the last 10 years, alterna-
tive therapeutic regimens with low dose immunoglobulin
or using different antiviral agents have been evaluated.
In the attempt to lowering costs without decreasing the
efficacy, combination of lamivudine with intramuscular
immunoglobulin and/or therapeutic protocols including
low dose immunoglobulin regimens (400-800 UI/months)
have been investigated (34,35). Similarly, other investiga-
tors have explored individualized immunoglobulin dosing,
according to anti-hepatitis B surface (anti-HBs) titers. This
strategy could reduce the pharmacy cost of antiviral pro-
phylaxis but increases the complexity of the follow-up of
the patient and the work load for nurses and physician.
Currently the global recurrence rate with the different pro-
posed therapeutic protocols, including the association of
nucleos(t)ide analogs and immunoglobulin, is reported
around 0 and 10%, varying accordingly to the different
risk factors at the time of liver transplantation (34,36-38).
When considering patients with lamivudine-resistant he-
patitis B, prophylactic treatment with immunoglobulin and
lamivudine are less effective, resulting in recurrence rates
of 15-22% (39). In these patients the use of a different an-
tiviral agent (according to the resistance profile) in combi-
nation with immunoglobulin, should be considered, and
the treatment choice has to regard the resistance profile. In
this clinical setting, adefovir is probably the most explored
antiviral agent. When it is used in patients with lamivudine
resistance, the recurrence rate is 10% or lower (19).
The withdrawal of immunoglobulin, while long term
oral antiviral treatment, is a safe therapeutic strategy, at
least in patients with low risk of recurrence or in patients
without recurrence after a prolonged treatment with com-
bined lamivudine and immunoglobulin (40-45). In low-
risk patients, who were HBV-negative at the time of liver
transplantation, and received long term prophylaxis with
lamivudine, the recurrence rates were similar when they
received immunogloblulins for a short period of weeks or
indefinitely (40). The effect of early withdrawn of im-
munoglobulin, while on long-term lamivudine prophy-
laxis, leads to 8-18% recurrence. Compliance with oral
antivirals is critical for long-term outcome of this strategy
(41). 
Among low-risk patients after 12 months of im-
munoglobulin prophylaxis, other antiviral agents, such as
adefovir, have been investigated as an alternative to long-
term immunoglobulin (36). Similarly, newer high poten-
cy antivirals with a lower long-term resistance rate, are a
promising option in an attempt to reduce the duration of
immunoglobulin prophylaxis or to use low-dose regi-
mens (46). 
Active immunization with recombinant HBV vaccines
has been investigated as an alternative to long-term im-
munoglobulin in low-risk patients (47-49). Most patients
included in these studies had undetectable HBV replica-
tion and HBeAg-negative at the time of liver transplanta-
tion, did not show recurrent hepatitis B after the with-
drawal of immunoglobulin prophylaxis and had been
transplanted many years before, so they required a medi-
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um-low grade of immunosuppresion. Nevertheless, the
percentage of patients achieving protective anti-HBs
titers varies between the different reports, ranging from
82% reported in the Spanish series to 18% of the Italian
series (49,50). In the same way, the efficacy and the per-
sistency of protective titers have not been determined
among large series, thus the use of these therapeutic regi-
mens is not routinely recommended at present.
In conclusion, combined prophylaxis with hyperim-
mune immunoglobulin and lamivudine (that could be re-
placed by other antivirals according to the resistance pro-
file), is the most effective therapeutic regimen to prevent
hepatitis B recurrence after liver transplantation. Howev-
er the duration of immunoglobulin treatment is still mat-
ter of debate. 
Prophylactic strategies should be based in the risk level
at the time of transplantation and the virological status after
liver transplantation. In our opinion, high potency antivirals
agents and long-term immunoglobulin should be employed
for high risk patients, while for low- and intermediate risk
patients, less potent antivirals and early withdrawn im-
munoglobulin regimens should be considered (Fig. 1).
LIVER RECIPIENTS FROM ANTI-HBC-
POSITIVE DONORS
Prevalence of antibodies against the HBV core antigen
(anti-HBc) among liver donors varies according to the
prevalence of hepatitis B in different geographic areas. It
reaches 30-80% of liver donors in Asia and 10% in west-
ern countries (10-12% in Spain) (1,51, 52). 
Anti-HBc-positivity of the donor is the main risk fac-
tor for de novo hepatitis B in liver transplant recipients.
In older reports, patients who receive a graft form and
anti-HBc- positive donor have shown a poor survival,
but in the majority of recent series, survival among pa-
tients receiving an anti-HBc-positive graft is compara-
ble to that of recipients of anti-HBc-negative liver
(1,53,54). Serological status of the receptor and the viral
load in the graft, strongly determine the risk of de novo
hepatitis B among receptors of antiHBc-positive graft.
Without any prophylaxis, the risk of de novo hepatitis in
naïve patients receiving anti-HBc-positive graft is 40%
compared to 10% in recipients with antibodies against
HBV surface antigen (anti-HBs). This risk is similar
(13%) in recipients who only have anti-HBc, and is very
low (2%) in patients with both anti-HBc and anti-HBs
(55) (Table I). 
Among the several prophylactic regimens for the pre-
vention of de novo hepatitis B in anti-HBc-positive graft
recipients, long-term lamivudine is the most used. 
Depending on the serological status of the recipient, pa-
tients receiving prophylaxis with lamivudine have a risk of
developing de novo hepatitis B below 4% (53, 56,57). In
some centers lamivudine is combined with immunoglobu-
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(*) The only two drugs approved for use in patients with decompensated liver cirrhosis in Spain are lamivudine and  adefovir. 
Fig. 1. Proposed prophylactic and treatment protocol of hepatitis B before and after liver transplantation (lg: anti-hepatitis B hyperimmune immunoglo-
bulin; ADF: adefovir; LAM: lamivudine; TEL: telbivudine; ETC: entecavir; TDF: tenofovir).
Table I. Risk of de novo hepatitis B for liver recipients from
a donor with antibodies against HBV core antigen,
according to serological status of the recipient
Naïve Anti-HBc+ Anti-HBc + AntiHBs+
Without prophylaxis > 40% 13% < 2%
With prophylaxis 12% < 4% < 2%
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lin, however a real advantage of this strategy compared to
lamivudine alone has never been shown (58,59). 
Immunoglobulin prophylaxis is less effective than
lamivudine, leading to a 10% of de novo hepatitis B
among antiHBc-positive recipients and above 20% among
seronegative patients (60-62).
Lamivudine prophylaxis is almost universally accept-
ed and is strongly recommended in all liver recipients
rgardless their serological status, even in anti-HBc-posi-
tive recipients. According to the low rate of de novo he-
patitis in anti-HBc-positive recipients, prophylaxis could
be unnecessary in them.
TREATMENT OF HEPATITIS B IN LIVER
TRANSPLANTATION RECIPIENTS
At the present time, recurrence of hepatitis B occurs in
less than 20% of liver recipients 4 years after liver trans-
plantation (2). Among transplanted patients, HBV infec-
tion (de novo hepatitis or recurrent) could show an
 aggressive clinical course, characterized by a marked in-
flammation and rapidly progressive fibrosis. Cholestasic
fibrosing hepatitis is an exclusive hepatitis B pattern of
immunosuppresed patients. It is characterized by lobular
disarray, cholangiolar proliferation, severe fibrosis and
mild inflammation (63-65). Treatment of hepatitis B
among liver recipients is based on the same principles as
in not transplanted patients. However, in presence of an
aggressive clinical course, when a rapid suppression of
viral replication is required, high potency antiviral agents
should be used (66). As in non-transplanted patients, the
choice of treatment must be based on the previous antivi-
ral treatments, the resistance profile and the presence of
comorbidities, especially renal insufficiency.
Until the early 2000, the most used antiviral agents
against HBV have been interferon and lamivudine.
Nowadays, because of its limited efficacy and the risk of
graft rejection, interferon is not longer used in this clini-
cal setting. Similarly, due to the need of long-term treat-
ment and considering that lamivudine resistance rate rais-
es the 70% after 4-5 years of treatment, lamivudine
monotherapy is currently abandoned (67). The availabili-
ty of adefovir has changed the clinical course of lamivu-
dine-resistant recurrent hepatitis B, and it is effective and
safe among liver transplantation recipients (19,68,69).
However, adefovir treatment could lead to the emergence
of resistant strains or to incomplete suppression of viral
replication; moreover it is potentially nephrotoxic and its
dosage must be adjusted in patients with impaired renal
function.
Tenofovir is effective against lamivudine –resistant
strains and it is safe in the setting of liver transplantation.
Due to its good therapeutic index and the lower resis-
tance rate compared to adefovir, it could be a valuable
therapeutic option at least for patients with kidney dys-
function (70,71). Telbivudine, has a possible role in the
presence of adefovir resistant strains, however its safety
and efficacy have not been proven in liver recipients. 
Entecavir is highly effective in patients naïve for nu-
cleos(t)ide analogs. However its antiviral activity is limit-
ed among patients with lamivudine -resistant hepatitis B,
in whom a genotypic resistance to entecavir has been
found around 15% after 2 years of treatment (72). As the
other newer antiviral agents, entecavir is an attractive op-
tion for liver receptors; however safety and efficacy data
in this clinical setting are needed. 
CONCLUSIONS
Antiviral treatment is strongly recommended among
all candidates for liver transplantation with active hepati-
tis B infection. The ideal antiviral agent should have a
minimal risk of resistance and achieve a rapid viral sup-
pression. The goal of the treatment is to achieve a com-
plete suppression of viral replication at the time of liver
transplantation, in order to reduce the risk of recurrence
after transplantation. In Spain, lamivudine and adefovir
are the only two antiviral agents approved for patients
with decompensated liver cirrhosis; however, in specific
situations, the use of other agents, such as entecavir, teno-
fovir and telbivudine, should be considered accordingly
to the presence of comorbidities or previous antiviral re-
sistance.
Independently of the serological status of the recipients,
after transplantation, prophylaxis should be given without
delay. Immunoglobulin and one or two nucleot(s)ide
analogs selected considering the virological status should
be given. When prophylaxis has failed, hepatitis B recur-
rence has to be rapidly treated, according to the resistance
profile and comorbidities, as in non-transplanted patients.
Finally all HBsAg- negative patients receiving an HBcAb-
positive graft have to receive long-term prophylaxis with
lamivudine.
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